These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 28851243)

  • 21.
    Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
    Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings.
    Broman KK; Dossett LA; Sun J; Eroglu Z; Zager JS
    Expert Opin Drug Saf; 2019 May; 18(5):381-392. PubMed ID: 30977681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testing for
    Le Flahec G; Briolais M; Guibourg B; Lemasson G; Grippari JL; Ledé F; Marcorelles P; Uguen A
    J Clin Pathol; 2020 Feb; 73(2):116-119. PubMed ID: 31506288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma.
    Niessner H; Hüsch A; Kosnopfel C; Meinhardt M; Westphal D; Meier F; Schilling B; Sinnberg T
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects.
    Urner-Bloch U; Urner M; Jaberg-Bentele N; Frauchiger AL; Dummer R; Goldinger SM
    Eur J Cancer; 2016 Sep; 65():130-8. PubMed ID: 27497344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Strudel M; Ascierto PA
    Am J Clin Dermatol; 2017 Dec; 18(6):745-754. PubMed ID: 28537004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging targeted therapies for melanoma.
    Johnson DB; Pollack MH; Sosman JA
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):195-207. PubMed ID: 27148822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The window of opportunities for targeted therapy in BRAFwt/NRASwt/KITwt melanoma: biology and clinical implications of fusion proteins and other mutations.
    Berger M; Richtig G; Kashofer K; Aigelsreiter A; Richtig E
    G Ital Dermatol Venereol; 2018 Jun; 153(3):349-360. PubMed ID: 29600692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving patient outcomes to targeted therapies in melanoma.
    Eroglu Z; Smalley KS; Sondak VK
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):633-41. PubMed ID: 27137746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.
    Cai W; Nguyen MQ; Wilski NA; Purwin TJ; Vernon M; Tiago M; Aplin AE
    Cancer Res; 2022 Jul; 82(14):2625-2639. PubMed ID: 35657206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.
    Vanella V; Festino L; Trojaniello C; Vitale MG; Sorrentino A; Paone M; Ascierto PA
    Curr Oncol Rep; 2019 Jul; 21(9):76. PubMed ID: 31359162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma.
    Schuler M; Zimmer L; Kim KB; Sosman JA; Ascierto PA; Postow MA; De Vos FYFL; van Herpen CML; Carlino MS; Johnson DB; Berking C; Reddy MB; Harney AS; Berlin JD; Amaria RN
    Clin Cancer Res; 2022 Jul; 28(14):3002-3010. PubMed ID: 35294522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.
    Bardia A; Gounder M; Rodon J; Janku F; Lolkema MP; Stephenson JJ; Bedard PL; Schuler M; Sessa C; LoRusso P; Thomas M; Maacke H; Evans H; Sun Y; Tan DSW
    Oncologist; 2020 Jan; 25(1):e160-e169. PubMed ID: 31395751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.
    Nagler A; Vredevoogd DW; Alon M; Cheng PF; Trabish S; Kalaora S; Arafeh R; Goldin V; Levesque MP; Peeper DS; Samuels Y
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):334-344. PubMed ID: 31549767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. War against NRAS-Mutant Melanoma Using Targeted Therapies Remains Challenging.
    Moschos SJ
    Clin Cancer Res; 2022 Jul; 28(14):2977-2979. PubMed ID: 35587446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.
    Rebecca VW; Alicea GM; Paraiso KH; Lawrence H; Gibney GT; Smalley KS
    Pigment Cell Melanoma Res; 2014 Nov; 27(6):1154-8. PubMed ID: 25130256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NRAS mutant melanoma: Towards better therapies.
    Randic T; Kozar I; Margue C; Utikal J; Kreis S
    Cancer Treat Rev; 2021 Sep; 99():102238. PubMed ID: 34098219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.
    Vogel CJ; Smit MA; Maddalo G; Possik PA; Sparidans RW; van der Burg SH; Verdegaal EM; Heck AJ; Samatar AA; Beijnen JH; Altelaar AF; Peeper DS
    Pigment Cell Melanoma Res; 2015 May; 28(3):307-17. PubMed ID: 25728708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MEK inhibitors in oncology: a patent review (2015-Present).
    Mahapatra DK; Asati V; Bharti SK
    Expert Opin Ther Pat; 2017 Aug; 27(8):887-906. PubMed ID: 28594589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.